RT Journal Article
SR Electronic
T1 Patient-specific analysis of bicuspid aortic valve hemodynamics using a fully coupled fluid-structure interaction (FSI) model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.24.21265224
DO 10.1101/2021.10.24.21265224
A1 Tongran Qin
A1 Andrés Caballero
A1 Wenbin Mao
A1 Brian Barrett
A1 Norihiko Kamioka
A1 Stamatios Lerakis
A1 Wei Sun
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265224.abstract
AB Bicuspid aortic valve (BAV), the most common congenital heart disease, is prone to develop significant valvular dysfunction and aortic wall abnormalities. Growing evidence has suggested that abnormal BAV hemodynamics could contribute to the disease progression. In order to investigate the BAV hemodynamic, we performed 3D patient-specific fluid-structure interaction (FSI) simulations of BAV with fully coupled flow dynamics and valve motions throughout the cardiac cycle. The results showed that the flow during systole can be characterized by a systolic jet and two counter-rotating recirculation vortices. At peak systole, the jet was usually eccentric, with asymmetric recirculation vortices, and helical flow motion in the ascending aorta. The flow structure at peak systole was quantified using the vorticity, flow reversal ratio and helicity index at four locations from the aortic root to the ascending aorta. The systolic jet was evaluated using the metrics including the peak velocity, normalized flow displacement, and jet angle. It was found that both the peak velocity and normalized flow displacement (rather than jet angle) of the systolic jet showed a strong correlation with the vorticity and helicity index of the flow in the ascending aorta, which suggests that these two metrics can be used for noninvasive evaluation of abnormal flow patterns in BAV patients.Competing Interest StatementDr. Wei Sun is a co-founder and serves as the Chief Scientific Advisor of Dura Biotech. He has received compensation and owns equity in the company. The remaining authors have nothing to disclose.Funding StatementThis study was supported in part by the NIH R01HL104036, and the Marvin H. and Nita S. Floyd Research Fund. Dr. Tongran Qin was in part supported by the American Heart Association (AHA) Postdoctoral Fellowship 19POST34450161. Dr. Andres Caballero was in part supported by a Fulbright-Colciencias Fellowship. Dr. Wenbin Mao was in part supported by the AHA 19CDA34660003 grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Broad (IRB) of Emory University and Georgia Institute of Technology gave ethical approval for this retrospective study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.